Vericel Corporation earnings
Latest results: Q3 2025
reported Nov 6, 2025
Vericel Corporation reported a record third quarter in 2025, driven by impressive revenue growth and significant profit improvements, highlighting strong momentum in its MACI and burn care products.
- Third quarter total revenue reached a record $67.5 million, exceeding guidance, with MACI revenue increasing 25% year-over-year to $55.7 million.
- Adjusted EBITDA margin stood at 25%, with GAAP net income surpassing $5 million and operating cash flow exceeding $22 million.
- The launch of MACI Arthro has resulted in a substantial increase in biopsy growth, with over 800 trained surgeons, enhancing overall implant and revenue growth.
Next report: February 25, 2027 (estimated) · Earnings calendar
Your portfolio
Track earnings for the stocks you own
Add your portfolio once, by connecting your broker or importing your history. When a company you hold reports, you get a recap like this one by email, with how the stock moved.